The roles of neuroticism, genetic susceptibility, and amygdala structure in chronic musculoskeletal pain onset and recovery
- 1Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA USA
- 2Department of Computer, Modeling, Electronics and System Engineering, University of Calabria, Cosenza, Italy
- 3Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA USA
Abstract
Background: Chronic musculoskeletal pain (CMP) represents a significant global health burden, yet the neurobiological mechanisms underlying its development remain poorly understood. This study investigates the complex interplay between neuroticism, genetic risk, and amygdala morphology in CMP onset, recovery, and pain characteristics using UK Biobank data.
Methods: We conducted longitudinal analyses on (1) 9382 pain-free individuals followed for CMP development and (2) 3460 CMP patients tracked for recovery outcomes. Neuroticism was quantified via a validated 12-item questionnaire assessing psychological distress. To assess chronic pain trajectories, we examined polygenic risk scores (PRS) for CMP and neuroticism, along with amygdala grey matter volumes, as predictors. Multivariate logistic and linear regression models were employed, followed by mediation analyses to elucidate underlying relationships between variables. Analyses were restricted to individuals of European ancestry.
Results: We found that higher neuroticism scores, neuroticism PRS, and CMP PRS were significantly associated with increased risk of CMP onset and reduced likelihood of recovery across cohorts (all Pcorrected < 0.05). Both neuroticism scores and PRS were positively correlated with pain intensity, whereas CMP PRS were not. Additionally, amygdala grey matter volumes were significantly associated with neuroticism in the CMP onset cohort but not in the recovery group. Neuroticism mediated the relationship between CMP PRS and subsequent CMP onset with a small effect size, while no mediation was observed for CMP recovery.
Conclusions: This study demonstrated significant associations between neuroticism, genetic factors, and amygdala morphology in CMP trajectories, highlighting a potential neurobiological mechanism linking psychological vulnerability to chronic pain. These results underscore the importance of integrating psychological assessment and targeted interventions into comprehensive pain management strategies.
Related
- Beyond network structure: How heterogeneous susceptibility modulates the spread of epidemics
- Questionable mediated effect of adolescent neuroticism on short-form video overuse: A comment on Liu and Wu (2026)
- Patterns and health relevance of neuroticism in Chinese men and women: evidence from the China Kadoorie Biobank
- Cannabinoid modulation of central amygdala population dynamics during threat investigation
- Impact of circadian rhythm disruptions on the emotional brain: gray matter and functional connectivity changes in the amygdala
BibTeX
@article{cannistra2026roles,
title = {{The roles of neuroticism, genetic susceptibility, and amygdala structure in chronic musculoskeletal pain onset and recovery}},
author = {Mattia Cannistra and Yu Liu and Valeria Sacca and Sierra Hodges and Lynn Pham and Pierangelo Veltri and Phil Hyoun Lee and Jian Kong},
journal = {Communications Medicine},
year = {2026},
month = jul,
doi = {10.1038/s43856-026-01754-9},
url = {https://doi.org/10.1038/s43856-026-01754-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The roles of neuroticism, genetic susceptibility, and amygdala structure in chronic musculoskeletal pain onset and recovery
AU - Mattia Cannistra
AU - Yu Liu
AU - Valeria Sacca
AU - Sierra Hodges
AU - Lynn Pham
AU - Pierangelo Veltri
AU - Phil Hyoun Lee
AU - Jian Kong
PY - 2026
DA - 2026/07/06
JO - Communications Medicine
DO - 10.1038/s43856-026-01754-9
UR - https://doi.org/10.1038/s43856-026-01754-9
AB - Background: Chronic musculoskeletal pain (CMP) represents a significant global health burden, yet the neurobiological mechanisms underlying its development remain poorly understood. This study investigates the complex interplay between neuroticism, genetic risk, and amygdala morphology in CMP onset, recovery, and pain characteristics using UK Biobank data. Methods: We conducted longitudinal analyses on (1) 9382 pain-free individuals followed for CMP development and (2) 3460 CMP patients tracked for recovery outcomes. Neuroticism was quantified via a validated 12-item questionnaire assessing psychological distress. To assess chronic pain trajectories, we examined polygenic risk scores (PRS) for CMP and neuroticism, along with amygdala grey matter volumes, as predictors. Multivariate logistic and linear regression models were employed, followed by mediation analyses to elucidate underlying relationships between variables. Analyses were restricted to individuals of European ancestry. Results: We found that higher neuroticism scores, neuroticism PRS, and CMP PRS were significantly associated with increased risk of CMP onset and reduced likelihood of recovery across cohorts (all Pcorrected < 0.05). Both neuroticism scores and PRS were positively correlated with pain intensity, whereas CMP PRS were not. Additionally, amygdala grey matter volumes were significantly associated with neuroticism in the CMP onset cohort but not in the recovery group. Neuroticism mediated the relationship between CMP PRS and subsequent CMP onset with a small effect size, while no mediation was observed for CMP recovery. Conclusions: This study demonstrated significant associations between neuroticism, genetic factors, and amygdala morphology in CMP trajectories, highlighting a potential neurobiological mechanism linking psychological vulnerability to chronic pain. These results underscore the importance of integrating psychological assessment and targeted interventions into comprehensive pain management strategies.
SN - 2730-664X
ER -